Search / Trial NCT00000146

Optic Neuritis Treatment Trial (ONTT)

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Trial Information

Current as of November 14, 2024

Unknown status

Keywords

ClinConnect Summary

Optic neuritis is an inflammatory disease of the optic nerve that typically affects young adults. Women are affected more often than men. It is second only to glaucoma as the most common acquired optic nerve disorder in persons younger than age 50.

In this disorder, closely linked to multiple sclerosis, prognosis for visual recovery is generally good. However, return of visual function is almost never complete. After resolution of optic neuritis, virtually all patients show some signs of optic nerve damage, and most are symptomatic. Even when a patient's acuity recovers to 20/20, abnormali...

Gender

ALL

Eligibility criteria

  • The major eligibility criteria for enrollment into the ONTT included the following:
  • Age range of 18 to 46 years
  • Acute unilateral optic neuritis with visual symptoms for 8 days or less
  • A relative afferent pupillary defect and a visual field defect in the affected eye
  • No previous episodes of optic neuritis in the affected eye
  • No previous corticosteroid treatment for optic neuritis or multiple sclerosis
  • No systemic disease other than multiple sclerosis that might be the cause of the optic neuritis

About National Eye Institute (Nei)

The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.

Locations

Little Rock, Arkansas, United States

San Francisco, California, United States

Washington, District Of Columbia, United States

Gainesville, Florida, United States

Chicago, Illinois, United States

Iowa City, Iowa, United States

Baltimore, Maryland, United States

Ann Arbor, Michigan, United States

East Lansing, Michigan, United States

New York, New York, United States

Durham, North Carolina, United States

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Houston, Texas, United States

Seattle, Washington, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials